{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:28:02Z","timestamp":1786343282500,"version":"build-2736575974"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016962","name":"Department of Science and Innovation, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    Monoclonal antibodies hold significant promise for preventing HIV infection in infants and children. However, global access remains constrained by the high production costs and infrastructure requirements associated with complex mammalian cell manufacturing platforms. Alternative expression systems, including plant-based production, have been proposed as scalable and potentially lower-cost approaches for antibody manufacturing. Here, we evaluated the\n                    <jats:italic>in vivo<\/jats:italic>\n                    performance of plant-produced CAP256-VRC26.25, a potent V2-apex HIV-1 broadly neutralizing antibody originally isolated from an HIV-infected individual in South Africa. Purified, endotoxin-free plant-produced CAP256-VRC26.25 was administered to cynomolgus macaques alongside a mammalian cell-produced CAP256-VRC26.25 control antibody prior to mucosal SHIV challenge. While the mammalian-derived antibody conferred protection, the plant-produced antibody did not. Pharmacokinetic analysis revealed approximately two orders of magnitude lower circulating antibody levels and rapid clearance of the plant-produced antibody, despite preserved\n                    <jats:italic>in vitro<\/jats:italic>\n                    neutralization potency. Electrophoretic analysis indicated evidence of partial proteolytic nicking of the plant-produced antibody, suggesting that structural instability may have contributed to reduced\n                    <jats:italic>in vivo<\/jats:italic>\n                    durability. Previous studies have shown that manufacturability liabilities within the CAP256-VRC26 lineage can occur across multiple expression platforms, highlighting the importance of integrating antibody engineering with manufacturing platform development. These findings have informed ongoing work combining host genome engineering to reduce endogenous plant protease activity with targeted modification of predicted protease-sensitive sites within CAP256-VRC26.25. Overall, this study provides translational insights into the engineering challenges associated with scalable production of broadly neutralizing antibodies and highlights key considerations for developing accessible antibody-based interventions for pediatric HIV prevention.\n                  <\/jats:p>","DOI":"10.3389\/fped.2026.1837801","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:31:28Z","timestamp":1786339888000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational insights into manufacturability and stability of broadly neutralizing antibodies for pediatric HIV prevention: lessons from plant-produced CAP256-VRC26.25"],"prefix":"10.3389","volume":"14","author":[{"given":"Tsepo L.","family":"Tsekoa","sequence":"first","affiliation":[{"name":"Future Production: Chemicals Cluster, Council for Scientific and Industrial Research","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusisizwe","family":"Kwezi","sequence":"additional","affiliation":[{"name":"Future Production: Chemicals Cluster, Council for Scientific and Industrial Research","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyen","family":"Pillay","sequence":"additional","affiliation":[{"name":"Future Production: Chemicals Cluster, Council for Scientific and Industrial Research","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibongile","family":"Mtimka","sequence":"additional","affiliation":[{"name":"Future Production: Chemicals Cluster, Council for Scientific and Industrial Research","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maabo","family":"Moralo","sequence":"additional","affiliation":[{"name":"Future Production: Chemicals Cluster, Council for Scientific and Industrial Research","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabamba","family":"Alexandre","sequence":"additional","affiliation":[{"name":"Future Production: Chemicals Cluster, Council for Scientific and Industrial Research","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Nkolola","sequence":"additional","affiliation":[{"name":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[{"name":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]},{"name":"Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Chikwamba","sequence":"additional","affiliation":[{"name":"Future Production: Chemicals Cluster, Council for Scientific and Industrial Research","place":["Pretoria, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","year":"2026"},{"key":"B2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40985-017-0072-5","article-title":"The impact of programs for prevention of mother-to-child transmission of HIV on health care services and systems in sub-Saharan Africa-A review","volume":"38","author":"Mutabazi","year":"2017","journal-title":"Public Health Rev"},{"key":"B3","year":"2007"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2055-6640(20)30343-5","article-title":"Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs","volume":"4","author":"Abuogi","year":"2018","journal-title":"J Virus Erad"},{"key":"B5","volume-title":"HIV prevention 2025\u2013road map: Getting on Track to end AIDS as a Public Health Threat by 2030","year":"2022"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1097\/QAI.0b013e3181fbcb04","article-title":"A way forward: the national HIV\/AIDS strategy and reducing HIV incidence in the United States","volume":"55","author":"Millett","year":"2010","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5334\/aogh.4277","article-title":"Advancing the global fight against HIV\/Aids: strategies, barriers, and the road to eradication","volume":"89","author":"Kumah","year":"2023","journal-title":"Ann Glob Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101475","DOI":"10.1016\/j.smim.2021.101475","article-title":"Broadly neutralizing antibodies for HIV-1 prevention and therapy","volume":"51","author":"Julg","year":"2021","journal-title":"Semin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"103203","DOI":"10.1016\/j.ebiom.2020.103203","article-title":"Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the antibody mediated prevention (AMP) trials","volume":"64","author":"Huang","year":"2021","journal-title":"EBioMedicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e25829","DOI":"10.1002\/jia2.25829","article-title":"Broadly neutralizing monoclonal antibodies for HIV prevention","volume":"24","author":"Miner","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","article-title":"Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through fc engineering: a. Ko et al","volume":"35","author":"Ko","year":"2021","journal-title":"BioDrugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1216","DOI":"10.1002\/iid3.1216","article-title":"Preventing breast milk HIV transmission using broadly neutralizing monoclonal antibodies: one size does not fit all","volume":"12","author":"Van de Perre","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e71076","DOI":"10.1002\/hsr2.71076","article-title":"HIV and maternal-fetal immunity: challenges and strategies for reducing vertical transmission-A narrative review","volume":"8","author":"Obeagu","year":"2025","journal-title":"Health Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1097\/INF.0000000000002774","article-title":"Maternal intervention to prevent mother-to-child transmission of HIV: moving beyond antiretroviral therapy","volume":"40","author":"Mangold","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/infdis\/jiz532","article-title":"Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants","volume":"222","author":"Cunningham","year":"2020","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11904-025-00744-1","article-title":"Future of bNAbs in HIV treatment","volume":"22","author":"Tebas","year":"2025","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nbt.4305","article-title":"Biopharmaceutical benchmarks 2018","volume":"36","author":"Walsh","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","article-title":"Industrialization of mAb production technology: the bioprocessing industry at a crossroads","volume":"1","author":"Kelley","year":"2009","journal-title":"MAbs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing\u2013an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0003418","DOI":"10.1371\/journal.pgph.0003418","article-title":"Novel approaches to enable equitable access to monoclonal antibodies in low-and middle-income countries","volume":"4","author":"Malhotra","year":"2024","journal-title":"PLOS Global Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s44222-025-00301-w","article-title":"Manufacturing innovation is essential for monoclonal antibody affordability and access","volume":"3","author":"Gardner","year":"2025","journal-title":"Nat Rev Bioeng"},{"key":"B24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/BTT.S515078","article-title":"Advancing monoclonal antibody manufacturing: process optimization, cost reduction strategies, and emerging technologies","author":"Ranbhor","year":"2025","journal-title":"Biologics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.copbio.2019.11.005","article-title":"Molecular farming for therapies and vaccines in Africa","volume":"61","author":"Tsekoa","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-63052-1","article-title":"Plant-based production of highly potent anti-HiV antibodies with engineered posttranslational modifications","volume":"10","author":"Singh","year":"2020","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/plants9070842","article-title":"Plant molecular farming: a viable platform for recombinant biopharmaceutical production","volume":"9","author":"Shanmugaraj","year":"2020","journal-title":"Plants"},{"key":"B28","doi-asserted-by":"publisher","first-page":"912","DOI":"10.12688\/f1000research.8010.1","article-title":"The potential of plants as a system for the development and production of human biologics","volume":"5","author":"Chen","year":"2016","journal-title":"F1000Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/ijms23031326","article-title":"Improving protein quantity and quality\u2014the next level of plant molecular farming","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/ijms26125510","article-title":"Harnessing transient expression systems with plant viral vectors for the production of biopharmaceuticals in Nicotiana benthamiana","volume":"26","author":"Akher","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41578-021-00399-5","article-title":"Integrating plant molecular farming and materials research for next-generation vaccines","volume":"7","author":"Chung","year":"2022","journal-title":"Nature Reviews Materials"},{"key":"B32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/vaccines13020191","article-title":"Molecular farming for immunization: current advances and future prospects in plant-produced vaccines","volume":"13","author":"Vo","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1467-7652.2004.00062.x","article-title":"Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge","volume":"2","author":"Gomord","year":"2004","journal-title":"Plant Biotechnol J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11816-024-00910-8","article-title":"Green biotherapeutics: overcoming challenges in plant-based expression platforms","volume":"18","author":"Jadhav","year":"2024","journal-title":"Plant Biotechnol Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal1321","article-title":"Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jbiosc.2024.02.005","article-title":"Establishment of a novel cell line, CHO-MK, derived from Chinese hamster ovary tissues for biologics manufacturing","volume":"137","author":"Masuda","year":"2024","journal-title":"J Biosci Bioeng"},{"key":"B39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12033-024-01060-6","article-title":"From efficiency to yield: exploring recent advances in CHO cell line development for monoclonal antibodies","volume":"67","author":"Majumdar","year":"2025","journal-title":"Mol Biotechnol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e70127","DOI":"10.1002\/biot.70127","article-title":"Developments in the production of recombinant monoclonal antibodies","volume":"20","author":"Saha","year":"2025","journal-title":"Biotechnol J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00253-022-12342-x","article-title":"Progress in fed-batch culture for recombinant protein production in CHO cells","volume":"107","author":"Xu","year":"2023","journal-title":"Appl Microbiol Biotechnol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"115812","DOI":"10.1016\/j.addr.2026.115812","article-title":"Challenges and developments in the manufacturing of high-concentration biotherapeutic monoclonal antibodies","volume":"232","author":"Rathore","year":"2026","journal-title":"Adv Drug Delivery Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1080\/19420862.2016.1227901","article-title":"Techno-economic analysis of a transient plant-based platform for monoclonal antibody production","volume":"8","author":"Nandi","year":"2016","journal-title":"MAbs"},{"key":"B44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00018-015-2074-0","article-title":"Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles","volume":"73","author":"Virdi","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.4161\/mabs.36336","article-title":"Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV","volume":"6","author":"Paul","year":"2014","journal-title":"MAbs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.3390\/ijms25136856","article-title":"Stability engineering of recombinant secretory igA","volume":"25","author":"G\u00f6ritzer","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/pbi.14576","article-title":"Enhancing quality and yield of recombinant secretory IgA antibodies in Nicotiana benthamiana by endoplasmic reticulum engineering","volume":"23","author":"G\u00f6ritzer","year":"2025","journal-title":"Plant Biotechnol J"},{"key":"B48","doi-asserted-by":"publisher","first-page":"107488","DOI":"10.1016\/j.celrep.2020.03.052","article-title":"Structure of super-potent antibody CAP256-VRC26. 25 in complex with HIV-1 envelope reveals a combined mode of trimer-apex recognition","volume":"31","author":"Gorman","year":"2020","journal-title":"Cell Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","article-title":"Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial","volume":"10","author":"Mahomed","year":"2023","journal-title":"Lancet HIV"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2022.953654","article-title":"Transient proteolysis reduction of Nicotiana benthamiana-produced CAP256 broadly neutralising antibodies using CRISPR\/Cas9","volume":"13","author":"Singh","year":"2022","journal-title":"Front Plant Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1467-7652.2008.00344.x","article-title":"Preventing unintended proteolysis in plant protein biofactories","volume":"6","author":"Benchabane","year":"2008","journal-title":"Plant Biotechnol J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/biot.201300207","article-title":"The human anti-HIV antibodies 2F5, 2G12, and PG9 differ in their susceptibility to proteolytic degradation: down-regulation of endogenous serine and cysteine proteinase activities could improve antibody production in plant-based expression platforms","volume":"9","author":"Niemer","year":"2014","journal-title":"Biotechnol J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4161\/mabs.2.3.11780","article-title":"Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?","volume":"2","author":"Brezski","year":"2010","journal-title":"MAbs"},{"key":"B55","doi-asserted-by":"publisher","first-page":"17864","DOI":"10.1073\/pnas.0904174106","article-title":"Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge","volume":"106","author":"Brezski","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"Fcrn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B57","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6","article-title":"Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn","volume":"29","author":"Kim","year":"1999","journal-title":"Eur J Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"17876","DOI":"10.1038\/s41598-022-22435-2","article-title":"Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e3296","DOI":"10.1002\/btpr.3296","article-title":"Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development","volume":"38","author":"Gollapudi","year":"2022","journal-title":"Biotechnol Prog"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41587-021-00884-w","article-title":"Alternative hosts as the missing link for equitable therapeutic protein production","volume":"39","author":"Brady","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","article-title":"Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients","volume":"22","author":"Temrikar","year":"2020","journal-title":"Paediatr Drugs"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1837801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:31:30Z","timestamp":1786339890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1837801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":62,"alternative-id":["10.3389\/fped.2026.1837801"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1837801","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1837801"}}